Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Zimmer Biomet Holdings, Inc. (ZBH)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
117.61+0.70 (+0.60%)
At close: 04:04PM EDT
117.61 +0.02 (+0.02%)
After hours: 04:28PM EDT
Advertisement
Sign in to post a message.
  • b
    bill
    Can anyone tell me why Zimmer spun off Zimvie? The balance sheet looks great so it wasn’t just to get rid of debt.
  • S
    Scott
    Received my ZIMV shares from the spinoff today... Being 1 share of ZIMV was given for every 10 shares of ZBH held, I was expecting a drop in ZBH share price which was insignificant if at all. I don't know much about their Spinal and Dental businesses, so will wait to learn more before deciding what to do with my shares (sell / hold / buy more).
  • A
    Anonymous
    I just tripled my small position....it is down $9 because everyone is showing their forecast at $6.40 - $6.80 vs $7.92 concensus....however, if you read carefully, the forecast EXCLUDES the spinoff of ZimVie....so I believe their forecast is actually fairly in line with forecast.... Can't quite tell since the don't have a forecast for ZimVie....but I think this is a drastic misunderstood reaction... If someone knows more, please opine.
  • Y
    Yahoo Finance Insights
    Zimmer Biomet is up 4.92% to 126.61
  • A
    Anonymous
    Zimmer Biomet pending spin-off ZimVie provides FY22 guidance (122.83)
    Projected Year Ending December 31, 2022 revenues flat at $1 bln; adjusted EBITDA margin 13.1-13.6% (flat to 50bps improvement), and adjusted EPS of $2.10-2.30.

    Zimmer Biomet announced in February 2021 its intent to form a new independent, publicly traded company to optimize resource allocation and drive toward market leadership. That transaction process remains on track, with ZimVie's first day of trading as a standalone entity anticipated on March 1, 2022.

    Given this new info...their guidance at $6.40 - $6.80 without the above is good news.... The market doesn't seem to understand this....or am I missing something.
  • L
    Lynton
    Increasing the debt, renewed going forward pricing pressures, and the spin off of Dental and Spine (spinning off more than likely means they couldn't find a buyer, not marketable segments) makes the outlook in question. Agree it has been a tough year, but leadership doesn't seem to be reacting accordingly.
  • L
    Lynton
    The historical norm for a company in this sector growing high single digits and earnings in line, typically maintains a PE ratio between 20-30. Currently this company doesn't have the sales or earnings to support its 58+ PE ratio. Like the company sector, but not enough upside at current ratios.
  • L
    Lynton
    Some credit due for the spin the company executives put on a soft quarter. The inability to make meaningful debt reduction is a lingering concern. The company may not financially positioned to combat the never ending litigation processes (lawsuits, recalls, product liability issues) that regularly occurs in this type of business. The debt seems to be manageable, but only if the business dynamics remain positive. High profit core implant growth patterns are concerning. Leary that the new technology platforms being highlighted can add meaningful dollars to the bottom line. Nice technologies to talk about, but time will tell if they play out. Undoubtedly, the current political health care climate will reinstate pricing pressures going forward. Every quarter the company boasts how good their management team is, a little less bragging and a little more growth/profitability would be reassuring. The stock price is favorable because of the overall market, if the market begins to pull back, the price will pull back quickly without some real sales growth. Is the risk greater than the rewards?
  • L
    Lynton
    What a Disappointment!

    Revenues down (core business decreasing a real concern), Guidance lowered. Nearly all categories of expenses increasing. Like many, losing confidence in the direction this company is headed. May be time to move on.
  • L
    Lynton
    Watching Results

    Not expecting any Revenue movement. Zimmer purchased Biomet, combined Revenues roughly $8B, seven years later, Revenues roughly $8B. Revenue remains flat?

    Increasing expense ratios. Debt reported past Quarter increased to $7.85B. Did results make enough money to pay notes, or did debt increase again?

    EPS, past Quarter EPS $1.90 ($.67 profit, $1.23 write offs). Are adjusted earnings still being used to make the numbers work? Lets hope adjustments are turning into profits?

    Hoping for better results. Not interested in any more "Pent-Up" demand talk, or talk about vanity R&D projects.
  • S
    StockStuffer
    $ASYS conversation
    The robotic surgery market includes
    $MDT market cap 158B
    $ISRG market cap 94B
    $SYK market cap 91B
    $ZBH market cap 34B
    $EDAP
    A lesser known play that uses high frequency ultrasound to target cancer without the incision is EDAP if you want to broaden the portfolio. The robotics guides the waves and essentially burns the cancer cells killing them and the body takes care of the rest.
  • L
    Lynton
    OUCH!

    Institutional downgrades
    Credit Rating revisions

    The ability to keep borrowing money may get expensive for ZBH.
  • A
    Anonymous
    This market reaction makes no sense.....if you add their midpoint projection of $6.50 plus $2.20 for the spin, you get a total of $8.70....yet the stock is down on what would be record earnings ??? What am I missing ?
  • D
    DueDiligenceSmart
    AcelRx Pharmaceuticals, Inc.
    $PFE $MRK or $ZBH bidding war for ACRX... ACRX jumped 10% on Volume... news leak!
    Bullish
  • S
    Scott
    There seems to be a lot of confusion following the earnings report. I've decided to value off the worst case assumptions just to be safe. Based on that, ZBH still looks like a bargain for the long term investor. To be clear, I'm looking for no less than a 50%+ return over the next couple years. Once Covid headwinds subside, comps are going to be blown out of the water for at least 4 quarters in a row. Timing to be determined, but I'm happy to patiently wait it out.
  • L
    Lynton
    Good news sales coming back, bad news where's the money. $2 billion in sales and only $142 million in net. Seems like a big gap. Most of the large joint product lines supposedly have a 50%+ margin. Something seems out of line. $1.90 adjusted earnings, only $.67 in the pocket, versus $1.23 adjusted, company appears to be struggling finding dollars. This is confusing as the margins are supposedly high, and the sales are coming back. Where's the net profits?
  • L
    Lynton
    I'm out. Q3 Transcript expects Q4 to be similar to Q3 results (not good). Per Transcript, 2022 is expected to be flat in revenues, again similar to 2021. The current price reflects a premium for this stock, the numbers don't support this premium. It appears that a large increase in R&D expenses, more than likely company pushing all they can into this bucket to show investors they are working on additional R&D for the future. When in reality they may be collecting dollars to justify the earnings adjustments they have been reporting. I believe the large increase in R&D expenses will be audited for validity. With the outlook flat for Q4 and 2022, no dividend to help the cause, debt payments, and potential market turmoil, I am out until this company shows signs of growth.
  • B
    Borja
    I am out also. Worst is to see underperformance compared to peers. R&D investment is tricky as it may not be able to activate... and thus it may be expenditure only.
    I understand management bold decision but it may or may not work. Leading the industry may need to come from such bold decisions since ZB has tough competition.
    My view is keep an eye on them, they are on the edge of a cliff they can fall but also they cam reach the top to see the best views...
    They are loosing the match but the match is not over!
    Neutral
  • T
    The Batman
    50% drop in 1 month?! I used to own this stock. Anyone care to comment on what has happened (other than the obvious Covid stuff)?
  • a
    annie
    Does anyone have an opinion on the earnings tmrw.?
Advertisement
Advertisement